Extended-Release Pramipexole in Advanced Parkinson Disease
Neurol 77:767-774, Schapira, A.H.V.,et al, 2011
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Ropinirole 24-Hour Prolonged Release: Randomized, Controlled Study in Advanced Parkinson Disease
Neurol 68:1108-1115, Pahwa,R.,et al, 2007
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000
Clinical Characteristics of Pramipexole-Induced Peripheral Edema
Arch Neurol 57:729-732, Tan,E.K.&Ondo,W., 2000
The Catechol-O-Methyltransferase (COMT) Inhibitor Entacapone Enhances the Pharmacokinetic and Clinical Response to Sinemet CR in Parkinson's Disease
JNNP 68:589-594, Piccinni,P.,et al, 2000
Acute Orhtostatic Hypotension When Starting Dopamine Agonists in Parkinson's Disease
Arch Neurol 57:1461-1463, Kujawa,K.,et al, 2000
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Immediate-Release and Controlled-Release Carbidopa/Levodopa in PD, A 5-Year Randomized Multicenter Study
Neurol 53:1012-1019, Koller,W.C.,et al, 1999
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Safety and Efficacy of Pramipexole in Early Parkinson Disease
Parkinson Study Group, JAMA 278:125-1301997., , 1997
Clinical Evaluation of Pramipexole in Advanced Parkinson's Disease
Neurol 49:162-168, Lieberman,A.,et al, 1997
Efficacy of Pramipexole, A Novel Dopamine Agonist, As Monotherapy in Mild to Moderate Parkinson's Disease
Neurol 49:724-728, Shannon,K.M.,et al, 1997
Double-Blind Comparison of Pramipexole & Bromocriptine Trtm with Placebo in Advanced Parkinson's Disease
Neurol 49:1060-1065, Guttman,M.,et al, 1997
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Clinical Experience with Controlled-Release Carbidopa/Levodopa in Parkinson's Disease
Neurol 43:677-681, Pahwa,R.,et al, 1993
Standard & Controlled-Release Levodopa/Carbidopa in Fluctuating Parkinson's Disease on a Protein Redistribution Diet
Arch Neurol 48:402-405, Karstaedt,P.J.,et al, 1991
A Multi-Center, Double-Blind Study on Slow-Release Bromocriptine in the Treatment of Parkinson's Disease
Neurol 41:1598-1602, Mannen,T.,et al, 1991
A Comparison of Effects of Controlled-Release Levodopa (Madopar CR) with Levodopa in Late Parkinson's Disease
JNNP 53:220-223, MacMahon,D.G.,et al, 1990
A Double-Blind Crossover Comparison of Sinemet CR4 and Standard Sinemet 25/100 in Patients with Parkinson's Disease
JNNP 52:207-212, Cedarbaum,J.M.,et al, 1989
Efficacy of Sinemet CR4 in Subgroups of Patients with Parkinson's Disease
JNNP 52:83-88, Factor,S.A.,et al, 1989
Neuropsychological Effects of Brain Autograft of Adrenal Medullary Tissue for Treatment of Parkinson's Disease
Neurol 38:1442-1450, Ostrosky-Solis,F.,et al, 1988
Controlled-Release Carbidopa/Levodopa (CR4-Sinemet) in Parkinson's Disease Pts With & Without Motor Fluctuations
Neurol 38:1143-1146, Goetz,C.G.,et al, 1988
Treatment of Chronic Parkinson's Disease with Controlled-Release Carbidopa/Levodopa
Arch Neurol 45:861-864, Hutton,J.T.,et al, 1988
Controlled-Release Levodopa/Carbidopa. I. Sinemet CR3 Treatment of Response Fluctuations in Parkinson's Disease
Neurol 37:233-241, Cedarbaum,J.M.,et al, 1987
Controlled Release Levodopa Treatment of Motor Fluctuations in Parkinson's Disease
JNNP 50:194-198, Juncos,J.L.,et al, 1987
Parkinson's Disease & Motor Fluctuations:Long-Acting Carbidopa. Levodopa (CR-4-Sinemet)
Neurol 37:875-878, Goetz,C.G.,et al, 1987
Controlled-Release Levodopa/Carbidopa. II. Sinemet CR4 Treatment of Response Fluctuations in Parkinson's Disease
Neurol 37:1607-1612, Cedarbaum,J.M.,et al, 1987
Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations
Arch Neurol 44:1010-1012, Juncos,J.L.,et al, 1987